8-K: Supernus Pharmaceuticals' SPN-820 Phase 2b Trial Fails to Meet Primary Endpoint in Treatment-Resistant Depression

Supernus Pharmaceuticals announces that its Phase 2b study of SPN-820 for treatment-resistant depression did not achieve statistically significant improvement in depressive symptoms compared to placebo.

Summary

• Supernus Pharmaceuticals announced topline results from its Phase 2b study of SPN-820 in adults with treatment-resistant depression (TRD).
• The study, involving approximately 250 patients across 40 clinical sites, did not demonstrate a statistically significant improvement on the primary endpoint.
• The primary endpoint was the change from baseline in the Montgomery-sberg Depression Rating Scale (MADRS) total score to Week 4.
• SPN-820 showed an LS mean change of -12.3 with a standard error of 0.96, while the placebo group showed a change of -11.9 with a standard error of 0.96; the p-value was not significant.
• There was no treatment difference between SPN-820 and placebo in the change from baseline to Week 4 for the secondary endpoints.
• The safety profile of SPN-820 was consistent with previous clinical trials, showing few adverse events.
• Supernus plans to analyze the data further and discuss the future of the program with its development partner, Navitor Pharmaceuticals.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the failure of the Phase 2b trial to meet its primary endpoint, which is a significant setback for the SPN-820 program. While the safety profile was positive, the lack of efficacy overshadows this aspect.

Positives

• The safety profile of SPN-820 was consistent with previous clinical trials, showing few adverse events.

Negatives

• The Phase 2b study of SPN-820 did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the MADRS total score compared to placebo.
• There was no treatment difference between SPN-820 and placebo in the change from baseline to Week 4 for the secondary endpoints.

Risks

• The failure to meet the primary endpoint raises concerns about the efficacy of SPN-820 for treatment-resistant depression.
• The future of the SPN-820 program is uncertain and depends on further analysis and discussions with Navitor Pharmaceuticals.
• The company's ability to sustain and increase its profitability is subject to risks and uncertainties.
• The company's ability to raise sufficient capital to fully implement its corporate strategy is subject to risks and uncertainties.

Future Outlook

The company will continue to analyze the data from the Phase 2b study and discuss the future of the SPN-820 program with its development partner, Navitor Pharmaceuticals.

Management Comments

• 'We are disappointed that the trial did not meet its primary endpoint in this patient population,' said Jack Khattar, President and CEO of Supernus.
• Jack Khattar also thanked the patients, coordinators, investigators, and the development team at Supernus for their time and efforts in conducting the trial.

Industry Context

The failure of SPN-820 to meet its primary endpoint highlights the challenges in developing effective treatments for treatment-resistant depression, a significant unmet medical need in the central nervous system (CNS) therapeutic area.

Comparison to Industry Standards

• It is difficult to compare the results of this trial to industry standards without knowing the specific design and patient population of other similar trials.
• However, the failure to achieve statistical significance on the primary endpoint is a setback for Supernus, as many other companies are also developing treatments for depression, such as Axsome Therapeutics with AXS-05 and Sage Therapeutics with zuranolone.

Stakeholder Impact

• Shareholders may react negatively to the news of the failed trial.
• Employees involved in the SPN-820 program may face uncertainty regarding their roles.
• Patients with treatment-resistant depression will not have a new treatment option available in the near term.

Next Steps

• Supernus will analyze the data from the Phase 2b study.
• Supernus will discuss the future of the SPN-820 program with its development partner, Navitor Pharmaceuticals.

Key Dates